Brain-computer interfaces (BCIs) are transitioning from experimental laboratory devices to practical medical tools that can restore lost abilities like speech, vision, and movement. Researchers have demonstrated that BCIs can decode neural signals to control computers, tablets, robotic arms, and even restore partial vision to people with blindness. While the technology remains nascent with only hundreds of implant recipients worldwide, rapid advances in artificial intelligence and hardware design are accelerating progress toward wider adoption.

What Exactly Is a Brain-Computer Interface and How Does It Work?

A brain-computer interface connects the brain directly to an electronic device by detecting electrical signals generated by neurons and translating them into commands that control machines. The technology bypasses the body entirely, which makes it particularly valuable for people with paralysis or nerve damage between their brain and muscles. BCIs can work in multiple ways: some have electrodes that penetrate the brain tissue, others sit on top of the brain within the skull, and still others are non-invasive devices placed on the outside of the head.

The potential applications extend far beyond basic communication. BCIs can stimulate the brain with information from the outside world, potentially allowing people with vision loss to see or those with hearing loss to hear. They may also target specific brain areas linked to neurological and mental health disorders. Deep brain stimulation, a related but less sophisticated form of neurostimulation, has been used for decades to reduce tremors from Parkinson's disease.

What Breakthroughs Have Researchers Actually Achieved?

The progress in BCI technology over the past few years has been remarkable. Early demonstrations showed individuals moving a cursor on a computer screen with their thoughts. Today, experimental wireless devices enable people to operate computers, tablets, and smart home gadgets using only their minds. Some users have successfully manipulated robotic arms to pick up and move objects.

One of the most significant advances involves restoring speech. Researchers at Stanford University and the University of California, Berkeley, have pioneered BCIs that decode "inner speech," where the device picks up signals from the brain when a person thinks about what they want to say and translates those thoughts into words on a screen. This represents a major step forward from earlier technology that could only recognize "attempted speech," which involves neural signals generated when someone tries to physically produce speech rather than simply imagining words.

Vision restoration has also made dramatic strides. The startup Science has developed an ultrathin, wireless microchip designed to replace the function of damaged photoreceptors on the retina. The PRIMA implant, which is awaiting regulatory approval for commercial use, is placed on the back of the eye and receives infrared light signals from high-tech glasses that capture images of the outside world. The chip converts this light into electrical stimulation for the brain, enabling vision-impaired people to see shapes and even read text. While it currently provides only black-and-white vision, this represents a substantial improvement over previous technology that allowed people to see only flashes of light. Science announced in March that it had closed a $230 million funding round as it expands clinical trials and prepares to bring PRIMA to market.

How to Understand the Current Limitations of BCI Technology

• Surgical Risk: Implanting electrodes into or onto the brain requires surgery, which carries inherent risks. Pushing material into the brain's surface can result in scar tissue formation, which may disrupt the connection between the device and the brain tissue.
• Practical Accessibility: While some implants are wireless and ready for at-home use, many others remain physically connected to computers or are restricted to laboratory settings for testing, making them impractical for everyday patient use.
• Signal Clarity: There is ongoing debate among researchers about how close an interface needs to be to the brain in order to read useful information and stimulate neurons effectively, with trade-offs between invasiveness and signal quality.

Despite these challenges, companies and researchers are exploring alternative approaches. California-based Science Corp. is developing a "biohybrid" device that uses a layer of neurons to form a bridge with brain tissue instead of relying on wires. Many companies are also experimenting with sound waves instead of electrical signals. In the United States, startups Merge Labs, co-founded by OpenAI CEO Sam Altman, and Nudge, founded by crypto billionaire Fred Ehrsam, are pursuing ultrasound-based approaches. In China, Gestala, co-founded by Chinese internet billionaire Chen Tianqiao, emerged this year as the country's first BCI company focused on ultrasound technology.

Why Are Billionaires and Major Tech Companies Betting on Brain-Computer Interfaces?

The potential of BCIs has attracted significant investment and attention from high-profile figures in technology and business. Tesla Chief Executive Officer Elon Musk and OpenAI CEO Sam Altman are among the billionaires betting that these devices will eventually become everyday consumer technology capable of unlocking superhuman powers. This level of interest reflects confidence that the industry is reaching an inflection point, driven by rapid advances in both hardware and artificial intelligence models that can decode neural signals more accurately than ever before.

The commercial applications extend well beyond medical use. Some researchers envision consumers using BCIs to question AI chatbots with their thoughts and receive answers through headphones, or soldiers piloting drones with their thoughts. However, widespread adoption faces significant barriers, including the need to demonstrate safety and efficacy in larger populations, regulatory approval processes, and the challenge of making the technology accessible and affordable to the general public.

The brain-computer interface field remains in its early stages, with only a few companies having received regulatory approval to move beyond clinical trials to commercial use, and even those approvals are limited to specific applications. Yet the convergence of improved hardware design, advances in artificial intelligence for signal decoding, and substantial investment from both established tech companies and startups suggests that BCIs may transition from science fiction to practical reality far more quickly than many expected just a few years ago.